The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).
 
Noel W. Clarke
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ferring; ipsen; Janssen-Cilag; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen-Cilag; Sanofi
Speakers' Bureau - Astellas Pharma; Astellas Pharma; AstraZeneca; Janssen-Cilag; Janssen-Cilag
Research Funding - AstraZeneca; Astrazeneca (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Epic Sciences; Exelixis; FORMA Therapeutics; GoodRx; IDEAYA Biosciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Antoine Thiery-Vuillemin
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Bayer (Inst); Ipsen (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche
 
Mototsugu Oya
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; Propella Therapeutics; Sanofi; Sema4; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure
 
Giuseppe Procopio
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb (BMS); Eisai; Ipsen; Janssen; Merck Sharp & Dohme; MSD Oncology; Novartis; Pfizer
Research Funding - Astellas Pharma; Ipsen; Janssen Oncology
 
João Daniel Cardoso Guedes
Honoraria - AstraZeneca; Daiichi Sankyo; Merck
Research Funding - Agenus; Amgen; AstraZeneca; Bayer; BRAVA; Bristol-Myers Squibb; Daiichi Sankyo; Eurofarma; Genentech; HUYA Bioscience International; Incyte; Lilly; MSD; Pfizer; PTC Therapeutics; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Gilead Sciences
 
Cagatay Arslan
No Relationships to Disclose
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology (Inst)
Research Funding - Astellas Pharma (Inst); AstraZeneca/Merck (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Roche
 
Francis Parnis
Stock and Other Ownership Interests - Telix Pharmaceuticals
Consulting or Advisory Role - Ipsen; Janssen Oncology; Merck Serono
Speakers' Bureau - AstraZeneca
Other Relationship - Bayer Schering Pharma
 
Emma Brown
Employment - Sciensus
Consulting or Advisory Role - Sciensus
 
Friederike Schlürmann
Honoraria - AAA/Endocyte/Novartis; Astellas Oncology; AstraZeneca; Bayer
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Oncology; AstraZeneca; Bayer
Speakers' Bureau - AAA/Endocyte/Novartis; Astellas Oncology; AstraZeneca; Bayer
Expert Testimony - AAA/Endocyte/Novartis; Astellas Oncology; AstraZeneca; Bayer
Travel, Accommodations, Expenses - AAA/Endocyte/Novartis; Astellas Oncology; AstraZeneca; Bayer
 
Jae Young Joung
Honoraria - Astellas Pharma; Johnson & Johnson/Janssen; Sanofi/Aventis
 
Mikio Sugimoto
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Kissei Pharmaceutical; Nippon Shinyaku; Novartis; Pfizer; Takeda
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics; PSMA Therapeutics; United Health Group
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Sanofi; Telix Pharmaceuticals; TeneoBio; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Yu-Zhen Liu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Laura Barker
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Paula Michelle del Rosario
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)